JP2022528851A5 - - Google Patents
Info
- Publication number
- JP2022528851A5 JP2022528851A5 JP2021557758A JP2021557758A JP2022528851A5 JP 2022528851 A5 JP2022528851 A5 JP 2022528851A5 JP 2021557758 A JP2021557758 A JP 2021557758A JP 2021557758 A JP2021557758 A JP 2021557758A JP 2022528851 A5 JP2022528851 A5 JP 2022528851A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- residue
- val
- cit
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023002495A JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826393P | 2019-03-29 | 2019-03-29 | |
| US62/826,393 | 2019-03-29 | ||
| US202062964177P | 2020-01-22 | 2020-01-22 | |
| US62/964,177 | 2020-01-22 | ||
| PCT/EP2020/057984 WO2020200880A1 (en) | 2019-03-29 | 2020-03-23 | Compounds and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002495A Division JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528851A JP2022528851A (ja) | 2022-06-16 |
| JP2022528851A5 true JP2022528851A5 (cg-RX-API-DMAC7.html) | 2022-08-24 |
| JP7210770B2 JP7210770B2 (ja) | 2023-01-23 |
Family
ID=69960637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557758A Active JP7210770B2 (ja) | 2019-03-29 | 2020-03-23 | 化合物及びその複合体 |
| JP2023002495A Active JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002495A Active JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Country Status (30)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| US11493668B2 (en) | 2018-09-26 | 2022-11-08 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| KR20240104214A (ko) * | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US20230097908A1 (en) * | 2020-01-22 | 2023-03-30 | Medimmune Limited | Compounds and conjugates thereof |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| TW202140076A (zh) * | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| EP4389732A4 (en) | 2021-08-17 | 2025-08-27 | Jiangsu Mabwell Health Pharmaceutical R&D Co Ltd | PROCESS FOR THE SYNTHESIS OF 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED IN THIS PROCESS |
| CN118414339A (zh) * | 2021-12-16 | 2024-07-30 | 迈威(上海)生物科技股份有限公司 | 一种喜树碱类化合物及其偶联物 |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| KR20240159839A (ko) | 2022-03-09 | 2024-11-06 | 아스트라제네카 아베 | FRα에 대한 결합 분자 |
| EP4490517A1 (en) | 2022-03-11 | 2025-01-15 | Astrazeneca AB | A scoring method for an anti-fr alpha antibody-drug conjugate therapy |
| MX2024011519A (es) | 2022-03-23 | 2024-09-24 | Synaffix Bv | Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario. |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| US20250205353A1 (en) | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| CA3253220A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | ANTIBODIES CONJUGATED FOR TARGETING TUMORS EXPRESSING TROP-2 |
| KR20240162575A (ko) | 2022-03-25 | 2024-11-15 | 자임워크스 비씨 인코포레이티드 | 엽산 수용체 알파를 표적화하는 항체-약물 접합체 및 사용 방법 |
| CN115160403B (zh) * | 2022-07-05 | 2025-06-27 | 博石丰生命科技(南通)有限公司 | 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法 |
| WO2024051762A1 (en) * | 2022-09-07 | 2024-03-14 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-trop2/egfr antibodies and uses thereof |
| TW202448517A (zh) | 2023-02-16 | 2024-12-16 | 瑞典商阿斯特捷利康公司 | 用治療性結合分子治療癌症的組合療法 |
| EP4701665A1 (en) | 2023-04-28 | 2026-03-04 | MedImmune Limited | B7-h4 therapeutic binding molecules for the treatment of cancer |
| IL324453A (en) * | 2023-05-12 | 2026-01-01 | Biocytogen Pharmaceuticals Beijing Co Ltd | Binding agent compounds and ligand-drug conjugates, methods of preparation and uses thereof |
| EP4721767A1 (en) | 2023-06-05 | 2026-04-08 | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. | Anti-b7-h3 antibody or fragment thereof, and antibody drug conjugate targeting b7-h3 |
| KR20260048598A (ko) | 2023-07-31 | 2026-04-10 | 아스트라제네카 아베 | Cd123 항체-약물 접합체 및 이의 사용 방법 |
| TW202540115A (zh) * | 2023-11-16 | 2025-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | 一種氘代喜樹鹼化合物及其製備和應用 |
| CN122374343A (zh) | 2023-11-30 | 2026-07-10 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| AU2024415931A1 (en) | 2023-12-27 | 2026-07-16 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Multi-specific antibody targeting her3 and trop2 and conjugate thereof |
| AU2025220091A1 (en) * | 2024-02-06 | 2026-08-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugate, preparation method therefor, and use thereof |
| CN122580121A (zh) * | 2024-02-06 | 2026-08-14 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
| WO2025191470A1 (en) | 2024-03-12 | 2025-09-18 | Astrazeneca Ab | Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads |
| WO2026057740A1 (en) | 2024-09-12 | 2026-03-19 | Astrazeneca Ab | Treatment of cancer with therapeutic binding molecules |
| WO2026078620A1 (en) | 2024-10-11 | 2026-04-16 | Medimmune Llc | Cd22 antibody and drug conjugates and uses thereof |
| WO2026115454A2 (en) | 2024-11-27 | 2026-06-04 | Astrazeneca Ab | Claudin 18.2 antibodies, antigen binding fragments and antibody drug conjugates thereof and methods of use in cancer therapy |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| JP2754022B2 (ja) * | 1988-11-18 | 1998-05-20 | 第一製薬株式会社 | カンプトテシン類縁体 |
| JP3024013B2 (ja) * | 1990-08-14 | 2000-03-21 | 杏林製薬株式会社 | フルオロエチルカンプトテシン誘導体 |
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| US6407115B1 (en) | 1991-01-16 | 2002-06-18 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
| US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| DK0811603T3 (da) | 1995-02-22 | 2002-12-16 | Daiichi Seiyaku Co | Aminotetralonderivater og fremgangsmåder til fremstilling af samme |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| JPH1095802A (ja) * | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
| IN189180B (cg-RX-API-DMAC7.html) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
| AR030207A1 (es) | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| US6403604B1 (en) * | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US6737548B2 (en) | 2001-05-08 | 2004-05-18 | Mitsui Chemicals, Inc. | Process for preparing 1,5-diaminonaphthalene derivative |
| UA80409C2 (en) | 2001-11-30 | 2007-09-25 | Chugai Pharmaceutical Co Ltd | Hexacyclic compounds |
| WO2004073601A2 (en) | 2003-02-21 | 2004-09-02 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic camptothecin derivatives |
| US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| NZ588884A (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
| WO2012096832A2 (en) * | 2011-01-12 | 2012-07-19 | Crystal Biopharmaceutical Llc | Hdac inhibiting derivatives of camptothecin |
| CN102850400A (zh) * | 2011-06-30 | 2013-01-02 | 周文强 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
| US10195288B2 (en) * | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| WO2014121033A1 (en) * | 2013-02-04 | 2014-08-07 | Fl Therapeutics Llc | Soluble complexes of drug analogs and albumin |
| CN115504924A (zh) * | 2013-11-27 | 2022-12-23 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| EP3733209A1 (en) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| CN114716506A (zh) | 2015-01-30 | 2022-07-08 | 苏特罗生物制药公司 | 用于偶联和治疗的哈米特林(hemiasterlin)衍生物 |
| GB201506393D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| MA43354A (fr) * | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2018066626A1 (ja) | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療 |
| US20190367605A1 (en) | 2016-11-10 | 2019-12-05 | Medimmune, Llc | Binding Molecules Specific For ASCT2 And Uses Thereof |
| JPWO2018110515A1 (ja) | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| SG11201906554RA (en) | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| US12667557B2 (en) | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| WO2019034177A1 (zh) | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| KR20240104214A (ko) * | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
-
2020
- 2020-03-23 KR KR1020247021308A patent/KR20240104214A/ko active Pending
- 2020-03-23 US US17/599,374 patent/US20220211863A1/en not_active Abandoned
- 2020-03-23 PT PT207138736T patent/PT3946464T/pt unknown
- 2020-03-23 BR BR112021018986A patent/BR112021018986A2/pt unknown
- 2020-03-23 LT LTEPPCT/EP2020/057984T patent/LT3946464T/lt unknown
- 2020-03-23 RS RS20221023A patent/RS63715B1/sr unknown
- 2020-03-23 KR KR1020237003605A patent/KR102679892B1/ko active Active
- 2020-03-23 EP EP20713873.6A patent/EP3946464B1/en active Active
- 2020-03-23 SG SG11202110524VA patent/SG11202110524VA/en unknown
- 2020-03-23 WO PCT/EP2020/057984 patent/WO2020200880A1/en not_active Ceased
- 2020-03-23 MX MX2021011812A patent/MX2021011812A/es unknown
- 2020-03-23 KR KR1020217035043A patent/KR102498681B1/ko active Active
- 2020-03-23 US US16/826,405 patent/US20200306243A1/en not_active Abandoned
- 2020-03-23 CN CN202410334103.5A patent/CN118240003A/zh active Pending
- 2020-03-23 HR HRP20221280TT patent/HRP20221280T1/hr unknown
- 2020-03-23 CN CN202080025199.7A patent/CN113631196B/zh active Active
- 2020-03-23 DK DK20713873.6T patent/DK3946464T3/da active
- 2020-03-23 AU AU2020252034A patent/AU2020252034B2/en active Active
- 2020-03-23 ES ES20713873T patent/ES2930295T3/es active Active
- 2020-03-23 CN CN202311084298.4A patent/CN117263948B/zh active Active
- 2020-03-23 HU HUE20713873A patent/HUE060364T2/hu unknown
- 2020-03-23 PL PL20713873.6T patent/PL3946464T3/pl unknown
- 2020-03-23 UA UAA202105856A patent/UA129129C2/uk unknown
- 2020-03-23 CA CA3133757A patent/CA3133757A1/en active Pending
- 2020-03-23 IL IL286291A patent/IL286291B2/en unknown
- 2020-03-23 PH PH1/2021/552363A patent/PH12021552363A1/en unknown
- 2020-03-23 EA EA202192554A patent/EA202192554A1/ru unknown
- 2020-03-23 CN CN202410334111.XA patent/CN118221763A/zh active Pending
- 2020-03-23 JP JP2021557758A patent/JP7210770B2/ja active Active
- 2020-03-23 SM SM20220439T patent/SMT202200439T1/it unknown
- 2020-03-23 CR CR20210541A patent/CR20210541A/es unknown
- 2020-03-23 EP EP22189090.8A patent/EP4176904A1/en active Pending
- 2020-03-27 TW TW112146860A patent/TWI886667B/zh active
- 2020-03-27 TW TW109110410A patent/TWI826676B/zh active
-
2021
- 2021-06-15 US US17/348,236 patent/US11446292B2/en active Active
- 2021-09-08 ZA ZA2021/06612A patent/ZA202106612B/en unknown
- 2021-09-27 CL CL2021002498A patent/CL2021002498A1/es unknown
- 2021-10-22 EC ECSENADI202178204A patent/ECSP21078204A/es unknown
- 2021-10-28 CO CONC2021/0014566A patent/CO2021014566A2/es unknown
-
2023
- 2023-01-11 JP JP2023002495A patent/JP7680658B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7447183B2 (ja) | 親水性抗体-薬物コンジュゲート | |
| HRP20221280T1 (hr) | Spojevi i njihovi konjugati | |
| JP2023512501A5 (cg-RX-API-DMAC7.html) | ||
| JP6117921B2 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| JP6843080B2 (ja) | システイン改変抗体の複合体 | |
| JP2025510629A (ja) | カンプトテシンコンジュゲート | |
| CA2944699C (en) | Affinity medicant conjugates | |
| JP2017537893A5 (cg-RX-API-DMAC7.html) | ||
| CA3207893A1 (en) | Immunomodulatory antibody-drug conjugates | |
| EA037203B1 (ru) | Конъюгаты антитело-лекарственное средство с самостабилизирующимися линкерами | |
| JP2021536430A (ja) | リンカー、それを含む抗体薬物コンジュゲート、およびその使用 | |
| JP2020512276A (ja) | ベンゾジアゼピン誘導体の選択的スルホン化 | |
| CN112601522A (zh) | 抗体-alk5抑制剂偶联物及其用途 | |
| JP2023511184A5 (cg-RX-API-DMAC7.html) | ||
| CA3164037A1 (en) | Alk5 inhibitor conjugates and uses thereof | |
| JP2017160205A (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| CN114269388A (zh) | 抗体-alk5抑制剂缀合物及其用途 | |
| US12280021B2 (en) | Affinity medicant conjugate | |
| WO2024023735A1 (en) | Auristatin derivatives and conjugates thereof | |
| JP5341314B2 (ja) | 薬物送出系 | |
| US20250241872A1 (en) | Affinity medicant conjugate | |
| HK40065597A (en) | Hydrophilic drug-linker compounds | |
| JP2019167359A (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| NZ722252B2 (en) | Hydrophilic antibody-drug conjugates | |
| NZ761642B2 (en) | Hydrophilic antibody-drug conjugates |